Sanara MedTech Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SMTI research report →
Range $35 – $35
Price Chart
About the company
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities.
- CEO
- Seth D. Yon
- IPO
- 1994
- Employees
- 108
- HQ
- Fort Worth, TX, US
Get TickerSpark's AI analysis on SMTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $298.90M
- P/E
- -91.44
- Fwd P/E
- 434.00
- PEG
- -0.77
- P/S
- 2.68
- P/B
- 37.43
- EV/EBITDA
- 45.25
- Div Yield
- 0.00%
- Gross Margin
- 91.83%
- Op Margin
- 7.20%
- Net Margin
- -2.69%
- ROE
- -42.22%
- ROIC
- 14.29%
Latest fiscal year · YoY change
- Revenue
- $103.12M+19.0%
- Gross Profit
- $92.94M+18.3%
- Op Income
- $9.15M
- Net Income
- $-37,562,606-288.7%
- EPS
- $-4.36-282.5%
- OCF Growth
- +28634.4%
- FCF Growth
- +953.9%
- 52W High
- $35.52
- 52W Low
- $16.05
- 50D MA
- $33.80
- 200D MA
- $26.21
- Beta
- 1.20
- RSI (14)
- 47
- Avg Volume
- 175.87K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sanara MedTech delivered a strong Q1 2026 with 19% revenue growth, higher margins, and a return to GAAP profitability, while reaffirming full-year guidance.· May 12, 2026
- Q1 net revenue rose 19% year over year, driven mainly by CellerateRX Surgical and BIASURGE.
- Gross margin improved to 93% and adjusted EBITDA increased 58% to $4.3 million.
- The company reported GAAP net income from continuing operations of $0.4 million, or $0.04 per diluted share, versus a loss last year.
- Management said the surgical-only strategy is resonating, with over 4,000 contracted/approved locations and more than 1,400 facilities sold into.
- Full-year 2026 revenue guidance was unchanged at $116 million to $121 million, and Q2 guidance calls for $28.5 million to $29.5 million in revenue.
First-quarter 2026 net revenue was $4.4 million higher year over year, up 19% versus Q1 2025. Gross profit increased $4.3 million, or 20%, to $25.9 million, and gross margin expanded about 100 basis points to 93% of net revenue. Operating income rose to $2.6 million from $0.8 million, adjusted EBITDA increased 58% to $4.3 million, and net income from continuing operations was $0.4 million, or $0.04 per diluted share, versus a $0.6 million loss, or $0.07 per diluted share, a year ago. For Q2 2026, management guided to net revenue of $28.5 million to $29.5 million, implying 10% to 14% year-over-year growth; full-year 2026 guidance remains $116 million to $121 million, or about 13% to 17% growth.
Seth Yon framed Q1 as validation of Sanara’s shift to a pure-play surgical company, saying it was the first full quarter of that focus and that results exceeded expectations. He emphasized strong demand, a record March sales month, and improving market penetration through a larger rep force, a broad distributor network, and expanding hospital/facility access. His tone was confident and constructive, with repeated references to a strengthened moat, product pipeline, and long-term growth.
Elizabeth Taylor highlighted the main financial gains: net revenue up 19%, gross profit up 20% to $25.9 million, and gross margin up to 93%. She noted operating expenses rose 12% to $23.2 million, but R&D fell to $0.8 million from $0.9 million and was 2.7% of sales; she said annual R&D should run at 5% to 7% of sales. She also pointed to a balance sheet with $13.6 million of cash and $46.2 million of long-term debt, and said the company paid debt service entirely in cash this quarter, which she called a milestone for free cash flow generation.
Analysts asked what drove the Q1 outperformance, and management pointed to CellerateRX, BIASURGE, early traction from the Vizient contract, and the company’s pure-play surgical repositioning; new reps were said to still be in training and not yet contributing materially. On guidance, Seth Yon said the company left the full-year outlook unchanged because Q1 was already expected to be strong and the Q1/Q2 cadence still fits the midpoint of the annual plan. In response to questions about moat-building and macro pressure on hospital budgets, management cited clinical evidence, economic evidence, pricing discipline, expanding IP/product enhancements, and said hospitals continue to scrutinize spend but Sanara’s products are positioned well in that environment.
The call showed real operating momentum: revenue grew 19%, margins expanded, adjusted EBITDA rose sharply, and the company reached GAAP profitability. Management also pointed to a larger sales force, more contracted hospitals, more facilities sold into, and a growing distributor base, suggesting the commercial footprint is widening. They sounded confident that the pure-play surgical strategy is starting to pay off and that cash generation is improving.
Management acknowledged several near-term constraints: Q1 is seasonally the slowest quarter, there was a three-day shipping shutdown in January, and new reps are still training before they contribute meaningfully. They also noted higher other expense from interest on the CRG term loan and equity-method losses, and cash used in operations was $2.5 million. Analysts raised concerns about hospital budget pressure, and management said hospitals are still scrutinizing spend inside the OR, which could slow adoption if the evidence and pricing story do not hold.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 34.6%
- Shares Outstanding
- 9.18M
- Float Shares
- 3.18M
of shares held by institutions
76 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 429.52K | ▲ 180.69K |
| Vanguard Capital Management LLC | 194.90K | 0 |
| Vanguard Group Inc | 183.14K | ▲ 1.10K |
| Qube Research & Technologies Ltd | 176.32K | ▲ 155.92K |
| Transmarket Holdings LP | 148.96K | ▲ 148.96K |
| Royal Bank Of Canada | 131.00K | ▼ 394 |
| Renaissance Technologies LLC | 114.10K | ▲ 46.70K |
| Gardner Lewis Asset Management L P | 112.46K | ▲ 112.46K |
| Aqr Capital Management LLC | 112.21K | ▲ 72.27K |
| Geode Capital Management, LLC | 105.35K | ▲ 16.17K |
| Alberta Investment Management Corp | 102.40K | ▲ 102.40K |
| Goldman Sachs Group Inc | 74.20K | ▲ 52.61K |
Held by 106 ETFs
Biggest fund positions in SMTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Yon Seth D | other | 3,661 |
| Jun 4, 26 | Salamone Ann Beal | other | 4,154 |
| Jun 4, 26 | Ortwein Sara N | other | 4,616 |
| Jun 4, 26 | Mack Roszell III | other | 5,308 |
| Jun 4, 26 | TANZBERGER ERIC D | other | 5,308 |
| Jun 4, 26 | Nixon Ronald T | other | 4,154 |
| Jun 4, 26 | DeSutter Robert Andrew | other | 5,539 |
| Jun 4, 26 | Major Eric D | other | 4,846 |
| Jun 4, 26 | Myers Keith G | other | 4,385 |
| May 15, 26 | Yon Seth D | other | 3,852 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SMTI coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SMTI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Alberta Investment Management Corp Acquires New Shares in Sanara MedTech Inc. $SMTI
defenseworld.net · Nov 17
Sanara MedTech Inc. (SMTI) Surpasses Q3 Earnings Estimates
zacks.com · Nov 12
Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)
globenewswire.com · Nov 12
15,945 Shares of Sanara MedTech Inc. $SMTI Bought by Bank of America Corp DE
defenseworld.net · Oct 5
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
gurufocus.com · Sep 11
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?
prnewswire.com · Sep 11
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
businesswire.com · Sep 10
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders
gurufocus.com · Aug 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
